MCM
LXRX icon

Masters Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Masters Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-500,000
Closed -$5.37M – 72
2015
Q3 		$5.37M Sell
500,000
-629,708
-56% -$6.88M 0.18% 44
2015
Q2 		$9.09M Sell
1,129,708
-8,059
-0.7% -$59.2K 0.3% 46
2015
Q1 		$7.52M Sell
1,137,767
-5,090
-0.4% -$34.8K 0.22% 53
2014
Q4 		$7.28M Buy
+1,142,857
New +$9.21M 0.2% 51

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

Masters Capital Management's LXRX Position: Q4 2015 in Review

Masters Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q4 2015, closing a stake of 500,000 shares — an estimated $5.37M sold.

Masters Capital Management first reported a position in LXRX in Q4 2014 and held it in 4 quarters. The position peaked at $9.09M in Q2 2015. 118 funds tracked by Wall St. Rank hold LXRX as of Q4 2015.

  • Masters Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • Masters Capital Management sold 500,000 Lexicon Pharmaceuticals shares in Q4 2015, an estimated $5.37M.
  • Masters Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2014 and held it in 4 quarters.
  • Masters Capital Management's Lexicon Pharmaceuticals position peaked at $9.09M in Q2 2015.
  • 118 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q4 2015.

Based on Masters Capital Management's 13F filing for Q4 2015, filed 16 Feb 2016.